Clinical Trials Directory

Trials / Completed

CompletedNCT00669019

Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

A Phase 2 Study of AZD0530 in Metastatic Melanoma

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
23 (actual)
Sponsor
National Cancer Institute (NCI) · NIH
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This phase II trial is studying how well saracatinib works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth

Detailed description

PRIMARY OBJECTIVES: I. To determine whether the Src kinase inhibitor, AZD0530 (saracatinib), has single agent clinical activity in patients with advanced melanoma. II. To determine whether this drug will increase progression-free survival of these patients from 3 months to 4.5 months. SECONDARY OBJECTIVES: I. To determine whether this drug may inhibit the activation of peripheral blood T cells analyzed ex vivo. OUTLINE: Patients receive saracatinib orally (PO) once daily (QD) in the absence of disease progression or unacceptable toxicity.

Conditions

Interventions

TypeNameDescription
DRUGsaracatinib

Timeline

Start date
2006-07-01
Primary completion
2011-01-01
Completion
2011-01-01
First posted
2008-04-29
Last updated
2014-05-21
Results posted
2014-01-27

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00669019. Inclusion in this directory is not an endorsement.